Zobrazeno 1 - 10
of 44
pro vyhledávání: '"Jean Yves Muller"'
Autor:
Olivier Garraud, Léna Absi, Danielle Rebibo, Jean-Yves Muller, Patricia Fromont, Evelyne Voitellier, Marie-Françoise Raynal, Philippe Verdier, Soizick Ducroz, Pascale Ruyer-Dumontier, Fabienne Quainon, Hélène Odent-Malaure
Publikováno v:
Clinical and Developmental Immunology, Vol 12, Iss 4, Pp 243-248 (2005)
Externí odkaz:
https://doaj.org/article/86cf37bb3df54676bb3dc07752d15a27
Autor:
I. Sandid, Claire Rieux, M. Carlier, G. Andreu, Elodie Pouchol, Paul-Michel Mertes, Yves Ozier, Jean-François Quaranta, Christian Drouet, Chantal Gautreau, Guillaume Fevre, Karim Boudjedir, Jean-Yves Muller, Benoit Clavier
Publikováno v:
Transfusion Medicine Reviews. 32:16-27
Using the French Hemovigilance Network database from 2007 to 2013, we provide information on demographics, incidence, and risk factors of reported transfusion-related acute lung injury (TRALI) and possible TRALI, analyze TRALI mitigation efforts for
Autor:
Marie Rimbert, Jean Yves Muller, Gilles Cambonie, Michel Rodière, Jacques Taïb, Eric Jeziorski, O. Plan, Aurélie Desenfants
Publikováno v:
American Journal of Perinatology. 28:461-466
Neonatal alloimmune neutropenia (NAN) results from neutrophil destruction by transplacental maternal neutrophil-specific immunoglobulin G (IgG) antibodies directed against the antigen inherited from the father. Treatment is usually based on recombina
Autor:
Agnes Mechoulan, Henri Jean Philippe, Bernard Branger, Yves Ville, Jean Yves Muller, Jean-François Oury, Norbert Winer, Cécile Kaplan
Publikováno v:
The Journal of Maternal-Fetal & Neonatal Medicine. 24:564-567
The aim of this study was to review recent multicenter data on antenatal management of anti-HPA-1a fetal alloimmune thrombocytopenia and, based on this retrospective study and on recent literature, to evaluate if FBS modified the obstetrical manageme
Publikováno v:
La Presse Médicale
La Presse Médicale, Elsevier Masson, 2015, 44 (2), pp.200-213. ⟨10.1016/j.lpm.2014.06.035⟩
La Presse Médicale, Elsevier Masson, 2015, 44 (2), ⟨10.1016/j.lpm.2014.06.035⟩
La Presse Médicale, Elsevier Masson, 2015, 44 (2), pp.200-213. 〈10.1016/j.lpm.2014.06.035〉
La Presse Médicale, Elsevier Masson, 2015, 〈10.1016/j.lpm.2014.06.035〉
La Presse Médicale, 2015, 44 (2), ⟨10.1016/j.lpm.2014.06.035⟩
La Presse Médicale, Elsevier Masson, 2015, 44 (2), pp.200-213. ⟨10.1016/j.lpm.2014.06.035⟩
La Presse Médicale, Elsevier Masson, 2015, 44 (2), ⟨10.1016/j.lpm.2014.06.035⟩
La Presse Médicale, Elsevier Masson, 2015, 44 (2), pp.200-213. 〈10.1016/j.lpm.2014.06.035〉
La Presse Médicale, Elsevier Masson, 2015, 〈10.1016/j.lpm.2014.06.035〉
La Presse Médicale, 2015, 44 (2), ⟨10.1016/j.lpm.2014.06.035⟩
International audience; L’acte transfusionnel repose sur la stricte application de mesures de sécurité immunologique qui écartent la survenue d’accidents aigus dès lors qu’ils peuvent être prévenus (comme la compatibilité ABO pour les co
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b3ae7de96e0f91ab738c7d4b085a7792
https://hal.archives-ouvertes.fr/hal-01133021
https://hal.archives-ouvertes.fr/hal-01133021
Publikováno v:
Annales de Dermatologie et de Vénéréologie. 133:543-548
Resume Introduction Le but principal de ce travail etait de definir la prevalence d’induction d’anticorps antinucleaires et d’anticorps antinucleosomes lors d’un traitement par interferon alpha a faible dose pendant 18 mois chez des malades a
Autor:
Jean-Yves Muller
Publikováno v:
EMC - Biologie Médicale. 1:1-7
Autor:
Jean-Yves Muller
Publikováno v:
EMC - Hématologie. 1:1-26
Autor:
Nathalie Valentin, Jean-Yves Muller
Publikováno v:
EMC - Biologie Médicale. 1:1-6
Publikováno v:
Rheumatology. 43:181-185
OBJECTIVE To estimate the performance characteristics of 10 commercial kits and one in-house kit for the detection and quantification of anticardiolipin (aCL) (six kits) and anti-beta2glycoprotein 1 (anti-beta2GP1) (five kits) antibodies, and to eval